Medtronic, Abbott Settle Longstanding Stent IP Battles For $400 Mil.
This article was originally published in The Gray Sheet
Executive Summary
Medtronic will pay Abbott Laboratories $400 million to resolve a costly series of global stent patent battles that have dragged on since the '90s and in some cases limited the companies' ability to commercialize in certain markets
You may also be interested in...
Boston Scientific Settles More Stent Patent Suits With J&J, For $1.7 Billion
The stent patent disarmament trend continued last week with the biggest settlement yet: Boston Scientific agreed Feb. 1 to pay Johnson & Johnson/Cordis $1.725 billion to settle three disputes dating back to 2003
Boston Scientific Settles More Stent Patent Suits With J&J, For $1.7 Billion
The stent patent disarmament trend continued last week with the biggest settlement yet: Boston Scientific agreed Feb. 1 to pay Johnson & Johnson/Cordis $1.725 billion to settle three disputes dating back to 2003
Boston Scientific Settles 14 Stent Patent Suits With J&J For $716 Million
Long-time stent rivals Boston Scientific and Johnson & Johnson signed a partial patent détente Sept. 29, but the companies are not finished battling over intellectual property for the profitable devices